208 related articles for article (PubMed ID: 36683488)
1. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
2. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
3. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Cheong EJY; Teo DWX; Chua DXY; Chan ECY
Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Tan HL; Tang LWT; Chin SY; Chan ECY
Drug Metab Pharmacokinet; 2021 Jun; 38():100390. PubMed ID: 33836300
[TBL] [Abstract][Full Text] [Related]
5. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
6. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
7. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Xu R; Ge W; Jiang Q
Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
[TBL] [Abstract][Full Text] [Related]
8. Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Cheong EJY; Ng DZW; Chin SY; Wang Z; Chan ECY
Br J Clin Pharmacol; 2022 May; 88(5):2267-2283. PubMed ID: 34837258
[TBL] [Abstract][Full Text] [Related]
9. Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine.
Ngo LT; Yang SY; Shin S; Cao DT; Van Nguyen H; Jung S; Lee JY; Lee JH; Yun HY; Chae JW
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1430-1442. PubMed ID: 36193622
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
Sia JEV; Lai X; Wu X; Zhang F; Li H; Cui C; Liu D
Eur J Pharm Sci; 2023 Mar; 182():106376. PubMed ID: 36626944
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the rivaroxaban-dronedarone interaction: insights from physiologically based pharmacokinetic modelling.
Hügl B; Horlitz M; Fischer K; Kreutz R
Eur Heart J Open; 2023 Jan; 3(1):oead004. PubMed ID: 36820238
[TBL] [Abstract][Full Text] [Related]
14. Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.
Ismail M; Lee VH; Chow CR; Rubino CM
J Clin Pharmacol; 2018 Apr; 58(4):541-548. PubMed ID: 29239000
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
Schaller S; Martins FS; Balazki P; Böhm S; Baumgart J; Hilger RA; Beelen DW; Hemmelmann C; Ring A
Br J Clin Pharmacol; 2022 Feb; 88(4):1722-1734. PubMed ID: 34519068
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Otsuka Y; Poondru S; Bonate PL; Rose RH; Jamei M; Ushigome F; Minematsu T
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
[TBL] [Abstract][Full Text] [Related]
20. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Karkhanis A; Lam HY; Venkatesan G; Koh SK; Chai CL; Zhou L; Hong Y; Kojodjojo P; Chan EC
Biochem Pharmacol; 2016 May; 107():67-80. PubMed ID: 26972388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
